113 related articles for article (PubMed ID: 10583272)
1. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system.
Sirohi B; Powles R; Mehta J; Raje N; Kulkarni S; Ramiah V; Saso R; Horton C; Bhagwati N; Singhal S; Treleaven J
Br J Haematol; 1999 Dec; 107(3):656-66. PubMed ID: 10583272
[TBL] [Abstract][Full Text] [Related]
2. The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients.
Sirohi B; Powles R; Mehta J; Treleaven J; Raje N; Kulkarni S; Rudin C; Bhagwati N; Horton C; Saso R; Singhal S; Parikh R
Med Oncol; 2001; 18(1):39-50. PubMed ID: 11778969
[TBL] [Abstract][Full Text] [Related]
3. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria.
Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Lal R; Singhal S; Mehta J; Horton C; Treleaven J
Bone Marrow Transplant; 2001 Jul; 28(1):29-37. PubMed ID: 11498741
[TBL] [Abstract][Full Text] [Related]
4. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma.
Raje N; Powles R; Kulkarni S; Milan S; Middleton G; Singhal S; Mehta J; Millar B; Viner C; Raymond J; Treleaven J; Cunningham D; Gore M
Br J Haematol; 1997 Apr; 97(1):153-60. PubMed ID: 9136958
[TBL] [Abstract][Full Text] [Related]
5. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
[TBL] [Abstract][Full Text] [Related]
7. Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression.
Somers LJ; Shaw B; Lyn BE; McMillan AM; Mahendra P
Clin Lab Haematol; 1998 Jun; 20(3):189-90. PubMed ID: 9681237
[TBL] [Abstract][Full Text] [Related]
8. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
[TBL] [Abstract][Full Text] [Related]
9. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
Davies FE; Forsyth PD; Rawstron AC; Owen RG; Pratt G; Evans PA; Richards SJ; Drayson M; Smith GM; Selby PJ; Child JA; Morgan GJ
Br J Haematol; 2001 Mar; 112(3):814-9. PubMed ID: 11260088
[TBL] [Abstract][Full Text] [Related]
10. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
11. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
12. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.
Forgeson GV; Selby P; Lakhani S; Zulian G; Viner C; Maitland J; McElwain TJ
Br J Cancer; 1988 Oct; 58(4):469-73. PubMed ID: 3207601
[TBL] [Abstract][Full Text] [Related]
13. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F
Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592
[TBL] [Abstract][Full Text] [Related]
14. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
15. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma.
Ross DM; To LB; Horvath N
Intern Med J; 2004; 34(9-10):576-8. PubMed ID: 15482273
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
Takeuchi J; Kyo T; Naito K; Sao H; Takahashi M; Miyawaki S; Kuriyama K; Ohtake S; Yagasaki F; Murakami H; Asou N; Ino T; Okamoto T; Usui N; Nishimura M; Shinagawa K; Fukushima T; Taguchi H; Morii T; Mizuta S; Akiyama H; Nakamura Y; Ohshima T; Ohno R
Leukemia; 2002 Jul; 16(7):1259-66. PubMed ID: 12094249
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
18. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T
Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497
[TBL] [Abstract][Full Text] [Related]
19. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
[TBL] [Abstract][Full Text] [Related]
20. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.
Singhal S; Powles R; Sirohi B; Treleaven J; Kulkarni S; Mehta J
Bone Marrow Transplant; 2002 Nov; 30(10):673-9. PubMed ID: 12420206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
